Investigational immunotherapy nearly doubles overall survival compared with docetaxel in advanced squamous NSCLC

Patients with metastatic squamous non-small compartment lung crab (NSCLC) whose illness progressed pursuing PD-(L)1 inhibitor therapy experienced a median wide endurance of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart, compared with 10.0 months for patients receiving docetaxel, according to updated findings from signifier 1 of the Phase III PRESERVE-003 trial.